At this stage, the health and safety of our people, clients, partners, and local communities are our utmost priority. FlexLink keeps operating while our associates are working safely, either from home or on site. We are pursuing our day to day activities and support our customers remotely.
Our supply chain is secured, we continue to ship spare parts, components, and equipment and do installations and commissionings where it is safe to do so. The current situation will not discourage us, but rather encourage a greater sense of responsibility to overcome these difficult times together.
EMA’s safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events – further updateNews:
EMA is working closely with the company, with experts in blood disorders, and with other health authorities including the UK’s MHRA based on its experience with around 11 million administered doses of the vaccine.
EMA’s investigation has been continuing over the weekend, and rigorous analysis of all the data related to thromboembolic events will be carried out in the coming days. Experts are looking in great detail at all the available data and clinical circumstances surrounding specific cases to determine whether the vaccine might have contributed or if the event is likely to have been due to other causes. EMA’s safety committee (PRAC) will further review the information tomorrow (Tuesday) and has called an extraordinary meeting on Thursday 18 March to conclude on the information gathered and any further actions that may need to be taken.
The COVID-19 pandemic is a global crisis, with devastating health, social and economic impact, and continues to be a major burden on EU health systems. Vaccines for COVID-19 help to protect individuals from becoming ill, especially healthcare professionals and vulnerable populations, such as older people or those with chronic diseases. While its investigation is ongoing, EMA currently remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19, with its associated risk of hospitalisation and death, outweigh the risks of side effects.
EMA will continue to communicate further as appropriate. In the meantime, anyone who has received the vaccine and has any concerns should contact an appropriate healthcare professional. It is important that people who suspect they may have a side effect after vaccination report this to the national medicines regulator, or to a healthcare professional who can help them do so.
More about the medicine
COVID-19 Vaccine AstraZeneca is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 is caused by SARS-CoV-2 virus. COVID-19 Vaccine AstraZeneca is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein from SARS-CoV-2. COVID-19 Vaccine AstraZeneca does not contain the virus itself and cannot cause COVID-19.
The most common side effects with COVID-19 Vaccine AstraZeneca are usually mild or moderate and improve within a few days after vaccination.
More about the procedure
The review of thromboembolic events with COVID-19 Vaccine AstraZeneca is being carried out in the context of a safety signal, under an accelerated timetable. A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine such as a vaccine and that warrants further investigation.
The review is being carried out by EMA's Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines. Once the review is completed, PRAC will make any recommendations necessary to minimise risks and protect patients' health.
The passive temperature control packaging solutions for the pharmaceutical, life science and cold chain logistics industries supported Pfizer with the development of the highly specialised and reusable ultra-low temperature (ULT) shipper to help them on the distribution of ultra-low temperature vaccines and storing them at Point of Use (POU) sites.
Ultra-Low Temperature vaccines, such as that developed by Pfizer – BioNTech, uses mRNA (messenger RNA) technology and must be stored at temperatures between -90°C to -60°C to ensure that the vaccine’s quality and efficacy is maintained.
The ULT shipper is capable of maintaining the required temperature during shipping of Covid-19 vaccines between -90°C to -60°C for at least 10 days unopened.
The highly innovative shipper utilises high performance insulation materials, incorporated in a robust and reusable construction, in conjunction with dry ice, to ensure long term ultra-low temperature control.
Based on current guidelines, the Softbox ULT Shipper can be opened twice a day, for up to three minutes at a time. This allows clinicians at Point of Use (POU) sites to access the vaccine vials required for each day’s immunisation clinics without exposing the remaining vaccine stored within the shipper to ambient temperatures, thus ensuring integrity of the vaccine is maintained.
When correctly managed, the ULT Shipper can be used to store vaccines for in excess of 30 days. Through a process called “Re-Icing” the dry ice in the Softbox ULT Shipper can be topped up ensuring maximum thermal protection of the highly temperature sensitive mRNA vaccines.
Tanya Alcorn, vice president, biopharma global supply chain for Pfizer, said: “Softbox’s extensive knowledge and experience in temperature control packaging solutions and the cold chain industry was the right choice for us. They immediately understood the unprecedented task at hand that was in front of us with the distribution of the vaccine, and quickly started to work with us to develop a unique packaging system that does not waste any precious vaccine and creates a seamless experience for customers. Their technical capabilities and innovative approach helped us achieve an excellent result in a very short period of time.”
Kevin Valentine, chief executive of Softbox, added: “We are immensely proud to be playing such an important role in the fight against Covid-19. We worked extremely hard during 2020 to help Pfizer develop this highly innovative ULT shipper; establishing one of the world’s largest fleets of reusable temperature-controlled parcel shippers in the process and setting up two world-class service centres to support ULT shipper refurbishment.”
“It’s a huge honour to have the opportunity to support the distribution of these vital vaccines at the right temperature, maintain their integrity and help save millions of lives.”
Softbox recently appointed a new technical solutions specialist who had previously worked at Pfizer.
An especially designed plastic - polyethylene terephthalate or PET is widely used for packaging water, medicines, beverages, edible oil, etc across the world because of its safety, utility and economic viability for the packaging of products of mass consumption. PET is a clear, strong, safe, lightweight and completely recyclable plastic belonging to the polyester family.
Recently, the principal bench of National Green Tribunal dismissed a litigation filed by Him, Jagriti Uttaranchal Welfare Society in 2014 stating that Indian government has already ensured guidelines for safe and regulated use of plastics for packaging and as the industry is adhering to global guidelines formulated under Pharmacopeia no further legislation changes are required.
The order comes after an expert committee set up by the Health Ministry in 2015, led by former biotech secretary Dr MK Bhan, submitted a report to the tribunal stating, “There is no conclusive evidence to suggest that use of PET or additive like antimony for pharmaceutical packaging may leach substances beyond limits that pose threat to human health.”
“This NGT order comes in at the right time to affirm that PET is safe. PET clearly is an inseparable packaging of several products,” says Dr Rao VSV Vadlamudi, Former President, Indian Pharmaceutical Association.
Sachin Sharma, Director, GEM Recycling states, “The safety of PET has been repeatedly demonstrated through extensive studies, regulatory approvals and scientific testing, as well as its widespread use and acceptance for more than three decades. The order must pave way for strengthening regulatory guidelines by prescribing specific methods for disposal of pharmaceutical packaging wastes.”
The new solution is available in plastic tube diameters ranging from 30-50mm, and in four substrate varieties: polyethylene and recycled tubes, each with or without EVOH barrier.
The reduction of material usage is most apparent in the tube’s wall thickness, which has been reduced from 0.5 mm to 0.35 mm without, Neopac says, sacrificing “exemplary” haptics. Low profile closures are already in the pipeline with the aim of achieving maximum weight reduction in plastic tubes.
Neopac estimates that, in its own packaging manufacturing operations, the new tubes will eliminate the need for as much as 4.6 tonnes of HDPE materials per one million tubes produced. This translates to an overall carbon footprint reduction of about 8.6 tons of CO2 per million tubes manufactured.
“Finding ways to reduce the overall amount of material is mandatory for packaging suppliers to move toward ambitious sustainability goals,” says Cornelia Schmid, head of marketing at Hoffmann Neopac.
“The challenge is always to boost a pack’s eco-friendliness without sacrificing product protection or aesthetics. The new lightweight tubes are viable solutions for brand owners in a number of industries, helping meet increasing consumer desires for comprehensive product sustainability.”
Constantia Flexibles has announces a new product called Perpetua, a sustainable high-barrier packaging solution for pharma products. It is the company’s first recyclable polymeric mono-material, has a wide range of uses in pharma packaging applications and is now available worldwide. Perpetua offers excellent product protection from oxygen, water vapor and light.
High protection levels against moisture, oxygen and heat are important for protecting active pharmaceutical ingredients (APIs), to provide the patient with an effective medication. Constantia Flexibles’ goal was to meet the very high barrier properties for pharma products, while implementing the best possible sustainability standards. The result is Perpetua, a recyclable product family, based on a unique line of full PP (Polypropylene) high barrier laminates. The flexible packaging solution is available in application-tailored versions. Being cyclos-HTP certified, its recyclability ranges from 90% to 96%, depending on the individual material specification, the company says.
The high barrier properties and lower environmental footprint do not limit the design possibilities of the packaging.
Pierre-Henri Bruchon, EVP Pharma Division Constantia Flexibles, comments, “Our mission is to constantly rethink packaging to make a meaningful contribution to our customers and the environment. Sustainability plays a decisive role in all our business activities. Therefore, the development of a more sustainable but at the same time high-barrier solution for pharma products like Perpetua was of high importance to us. It is the perfect packaging solution for pharma products.”
The innovative Syringe-Closure-Wrap marking solution features a label that wraps around the syringe barrel and the complete cap. When the user pulls off the upper part of the label, the integrated first-opening indication is triggered. Due to special security die cuts, the label is irreversibly destroyed and cannot be closed again unnoticed. After the label has been opened for the first time, an additional warning appears as a visible security element. For increased product and counterfeiting protection, overt, covert or digital authentication features can be integrated into the label.
Aptar Reports Fourth Quarter and Annual 2020 Results; Showcases Resilient Business with Strong Second Half Results and Record Annual Free Cash FlowNews:
Crystal Lake, Illinois, February 18, 2021 — AptarGroup, Inc. (NYSE:ATR) today reported fourth quarter and annual results for 2020 and highlighted the resiliency of the Company’s business model throughout the COVID-19 pandemic.
Fourth Quarter 2020 Summary
Strong fourth quarter performance — reported sales grew 12%; core sales (excluding acquisitions and currency effects) grew 5%
Double-digit sales growth for Pharma and Food + Beverage segments (reported and core sales) on broad based demand for our innovative solutions
Acquisitions contributed to Beauty + Home’s reported sales growth while core sales declined modestly — continued strong demand from personal care and home care markets was offset by a marginally improved, though still below prior year, beauty market and lower custom tooling sales
Reported earnings per share totaled $0.79 (an increase of 8% compared to the prior year)
Adjusted earnings per share totaled $0.92 (an increase of 8% compared to the prior year when neutralizing currency effects)
Achieved another quarter of strong cash flow from operations and free cash flow
Declared quarterly dividend of $0.36 per share
Annual 2020 Summary
Diversified business drove performance throughout the pandemic with considerable improvement in the second half of the year
Reported sales growth of 2% with core sales equal to the prior year
Reported earnings per share of $3.21 (a decrease of 12% compared to the prior year)
Adjusted earnings per share of $3.64 (a decrease of 9% compared to the prior year when neutralizing currency effects)
Earnings were negatively impacted by the effects of the global pandemic on the beauty and beverage markets
Record cash flow from operations of $570 million (an increase of 11% compared to the prior year)
Record free cash flow of $324 million (an increase of 19% compared to the prior year)
Achieved our 27th consecutive year of increasing our aggregate annual dividend amount, returning $93 million to shareholders
Acquired FusionPKG, a leader in high quality, prestige airless and color cosmetics packaging, and conception-to-launch turnkey solutions for the North American beauty market
Expanded portfolio of digital health offerings through a strategic investment in Sonmol, the acquisition of the assets of Cohero Health, and the launch of a connected inhaler program for respiratory diseases in India with Lupin Limited
Furthered our ESG commitments and received additional recognition (Newsweek’s Most Responsible Companies, Barron’s Most Sustainable Companies, CDP’s A List and Supplier Engagement leader, ISS ESG Prime Status, EcoVadis Gold)
High protection levels against moisture, oxygen and heat are important for protecting active pharmaceutical ingredients (APIs), to provide the patient with an effective medication. Constantia Flexibles’ goal was to meet the very high barrier properties for pharma products, while implementing the best possible sustainability standards. The result is Perpetua, a recyclable product family, based on a unique line of full PP (Polypropylene) high barrier laminates. The flexible packaging solution is available in application-tailored versions. Being cyclos-HTP* certified, its recyclability ranges from 90% to 96%, depending on the individual material specification.
The high barrier properties and lower environmental footprint do not limit the design possibilities of the packaging.
Rondo-Pak Takes Part in Puerto Rico Community Aid Initiative in Response to Recent Natural Disasters
Company’s contribution to “Backpacks of Hope” mission provides emergency supplies and resources to local residents.
- INDUSTRY UPDATES
- OUR PRODUCTS
- Our Partners